Logo image of BCRX

BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Fundamental Analysis

NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD

10.59  +0.2 (+1.92%)

After market: 10.5117 -0.08 (-0.74%)

Fundamental Rating

3

Taking everything into account, BCRX scores 3 out of 10 in our fundamental rating. BCRX was compared to 560 industry peers in the Biotechnology industry. Both the profitability and financial health of BCRX have multiple concerns. BCRX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BCRX had negative earnings in the past year.
BCRX had a negative operating cash flow in the past year.
In the past 5 years BCRX always reported negative net income.
In the past 5 years BCRX always reported negative operating cash flow.
BCRX Yearly Net Income VS EBIT VS OCF VS FCFBCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

BCRX has a Return On Assets of -11.14%. This is amongst the best in the industry. BCRX outperforms 84.34% of its industry peers.
With an excellent Return On Invested Capital value of 7.70%, BCRX belongs to the best of the industry, outperforming 93.77% of the companies in the same industry.
Industry RankSector Rank
ROA -11.14%
ROE N/A
ROIC 7.7%
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCRX Yearly ROA, ROE, ROICBCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Operating Margin of BCRX (6.59%) is better than 93.06% of its industry peers.
BCRX has a Gross Margin of 96.89%. This is amongst the best in the industry. BCRX outperforms 96.80% of its industry peers.
In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.
Industry RankSector Rank
OM 6.59%
PM (TTM) N/A
GM 96.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
BCRX Yearly Profit, Operating, Gross MarginsBCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

BCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, BCRX has more shares outstanding
The number of shares outstanding for BCRX has been increased compared to 5 years ago.
Compared to 1 year ago, BCRX has a worse debt to assets ratio.
BCRX Yearly Shares OutstandingBCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BCRX Yearly Total Debt VS Total AssetsBCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -1.78, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.78, BCRX perfoms like the industry average, outperforming 56.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.78
ROIC/WACC0.83
WACC9.25%
BCRX Yearly LT Debt VS Equity VS FCFBCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

BCRX has a Current Ratio of 2.93. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
BCRX has a worse Current ratio (2.93) than 65.84% of its industry peers.
A Quick Ratio of 2.88 indicates that BCRX has no problem at all paying its short term obligations.
BCRX's Quick ratio of 2.88 is on the low side compared to the rest of the industry. BCRX is outperformed by 64.77% of its industry peers.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.88
BCRX Yearly Current Assets VS Current LiabilitesBCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.45% over the past year.
Looking at the last year, BCRX shows a very strong growth in Revenue. The Revenue has grown by 41.67%.
Measured over the past years, BCRX shows a very strong growth in Revenue. The Revenue has been growing by 55.99% on average per year.
EPS 1Y (TTM)70.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)41.67%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%56.89%

3.2 Future

Based on estimates for the next years, BCRX will show a very strong growth in Earnings Per Share. The EPS will grow by 40.34% on average per year.
BCRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.39% yearly.
EPS Next Y107.19%
EPS Next 2Y69.99%
EPS Next 3Y58.32%
EPS Next 5Y40.34%
Revenue Next Year34.21%
Revenue Next 2Y23.25%
Revenue Next 3Y19.74%
Revenue Next 5Y15.39%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BCRX Yearly Revenue VS EstimatesBCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
BCRX Yearly EPS VS EstimatesBCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 27.68 indicates a quite expensive valuation of BCRX.
Based on the Price/Forward Earnings ratio, BCRX is valued cheaper than 90.75% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BCRX to the average of the S&P500 Index (21.77), we can say BCRX is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 27.68
BCRX Price Earnings VS Forward Price EarningsBCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BCRX is valued cheaply inside the industry as 91.46% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 74.08
BCRX Per share dataBCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

BCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BCRX's earnings are expected to grow with 58.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.99%
EPS Next 3Y58.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (5/23/2025, 9:15:16 PM)

After market: 10.5117 -0.08 (-0.74%)

10.59

+0.2 (+1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners80.14%
Inst Owner Change5.03%
Ins Owners1.42%
Ins Owner Change16.81%
Market Cap2.22B
Analysts83.16
Price Target17.51 (65.34%)
Short Float %9.01%
Short Ratio3.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.8%
Min EPS beat(2)-123.6%
Max EPS beat(2)100%
EPS beat(4)2
Avg EPS beat(4)9.03%
Min EPS beat(4)-123.6%
Max EPS beat(4)100%
EPS beat(8)4
Avg EPS beat(8)7.72%
EPS beat(12)7
Avg EPS beat(12)-1.59%
EPS beat(16)9
Avg EPS beat(16)2.12%
Revenue beat(2)1
Avg Revenue beat(2)5.78%
Min Revenue beat(2)-0.92%
Max Revenue beat(2)12.47%
Revenue beat(4)3
Avg Revenue beat(4)5.65%
Min Revenue beat(4)-0.92%
Max Revenue beat(4)12.47%
Revenue beat(8)5
Avg Revenue beat(8)3.67%
Revenue beat(12)6
Avg Revenue beat(12)2.17%
Revenue beat(16)8
Avg Revenue beat(16)5.36%
PT rev (1m)11.35%
PT rev (3m)12.4%
EPS NQ rev (1m)234.09%
EPS NQ rev (3m)192.3%
EPS NY rev (1m)139.3%
EPS NY rev (3m)134.08%
Revenue NQ rev (1m)7.78%
Revenue NQ rev (3m)9.54%
Revenue NY rev (1m)7.03%
Revenue NY rev (3m)10.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.68
P/S 4.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 74.08
EPS(TTM)-0.26
EYN/A
EPS(NY)0.38
Fwd EY3.61%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS2.41
BVpS-2.16
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.14%
ROE N/A
ROCE 9.75%
ROIC 7.7%
ROICexc 58.11%
ROICexgc 58.11%
OM 6.59%
PM (TTM) N/A
GM 96.89%
FCFM N/A
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
F-Score4
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 22.77
Cap/Depr 81.2%
Cap/Sales 0.2%
Interest Coverage 0.96
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.88
Altman-Z -1.78
F-Score4
WACC9.25%
ROIC/WACC0.83
Cap/Depr(3y)104.99%
Cap/Depr(5y)137.87%
Cap/Sales(3y)0.47%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y107.19%
EPS Next 2Y69.99%
EPS Next 3Y58.32%
EPS Next 5Y40.34%
Revenue 1Y (TTM)41.67%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%56.89%
Revenue Next Year34.21%
Revenue Next 2Y23.25%
Revenue Next 3Y19.74%
Revenue Next 5Y15.39%
EBIT growth 1Y136.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year588.75%
EBIT Next 3Y129.66%
EBIT Next 5YN/A
FCF growth 1Y79.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.35%
OCF growth 3YN/A
OCF growth 5YN/A